NL-OMON23112RecruitingNot Applicable
An open label, randomized phase III trial comparing 2.5 year duration of letrozole (Femara®) treatment with 5 year duration in patients previously treated for endocrine sensitive early breast cancer.
eiden University Medical Center (LUMC)0 sites1,823 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 1,823
Study Overview
Brief Summary
/A
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1. Postmenopausal at the time of randomization;
- •2. Histologically proven invasive breast cancer (stage I, II, or III) adequately treated at the time of diagnosis;
Exclusion Criteria
- •1. ER and PgR negative or unknown primary tumors;
- •2. Evidence of previous or current localized or distant breast cancer recurrence;
Investigators
Similar Trials
Active, not recruiting
Phase 1
Phase III study in first-line treatment of patients with metastatic colorectal cancer who are not candidate for intensive therapyMetastatic colorectal cancerMedDRA version: 21.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004059-22-CZInstitut de Recherches Internationales Servier856
Completed
Phase 3
Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast CancerBreast CancerNCT01712893Fudan University216
Active, not recruiting
Phase 1
A study of trifluridine/tipiracil and bevacizumab in patients with resistant colorectal cancer that has spread (metastatic)Refractory metastatic colorectal cancerMedDRA version: 21.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-001976-14-DEInstitut de Recherches Internationales Servier492
Active, not recruiting
Phase 1
A study of trifluridine/tipiracil and bevacizumab in patients with resistant colorectal cancer that has spread (metastatic)Refractory metastatic colorectal cancerMedDRA version: 21.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-001976-14-HUInstitut de Recherches Internationales Servier492
Active, not recruiting
Phase 1
A study of trifluridine/tipiracil and bevacizumab in patients with resistant colorectal cancer that has spread (metastatic)EUCTR2020-001976-14-ATInstitut de Recherches Internationales Servier492